タイトル無し

概要

論文の詳細を見る
Based on the determination of WASOG task force, clinical phenotypes were analyzed in sarcoidosis patients followed-up for more than 5 years in four hospitals: Sapporo Hospital of Hokkaido Railway Company, Japan Railway Tokyo General Hospital, Japanese Red Cross Medical Center and Kyoto University Hospital. Clinical phenotypes were subdivided into 9 types: 1) resolved, never treated; 2) resolved, no therapy for more than 1 year; 3) minimal disease, never treated; 4) minimal disease, no therapy for more than 1 year; 5) persistent, never treated; 6) persistent, no therapy for more than 1 year; 7) current therapy, asymptomatic; 8) current therapy, symptomatic; and 9) current therapy, worsening. There were from 2% to 44% in the resolved group, 3% to 15% in the minimal disease group, 3% to 28% in the persistent group, and 25% to 60% in the current therapy group. Current therapy includes oral corticosteroids, topical corticosteroids (eye drops and inhalation), immunosuppressants, anti-depressants, antibiotics, and NSAIDs. There was 1% to 45% (mean 21%) in the current therapy group on oral corticosteroids, suggesting that this subtype reflects the actual current therapy group.
日本サルコイドーシス/肉芽腫性疾患学会の論文